Evidence map›Paper›PMID 39228895›Full record

ArticleThe journal of allergy and clinical immunology. Global2024

Psychometric evaluation of the Dysphagia Symptom Questionnaire for adults and adolescents with eosinophilic esophagitis.

Eilish McCann, Kathryn A Peterson, Diane Whalley, Shanshan Qin, Sarette T Tilton, Siddhesh Kamat, Xian Sun, Evan S Dellon

Registry-linked trialAbstract read
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03633617 (A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03633617 phase3completednot on this map

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

TypeinterventionalSponsorRegeneron PharmaceuticalsRan2018 to 2022Enrolled321ConditionsEosinophilic EsophagitisArmsDupilumab, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026
    Review
  3. Patient-Reported Outcome Measures in Benign Esophageal Disorders.The American journal of gastroenterology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eilish McCannRegeneron Pharmaceuticals, Inc, Sleepy Hollow, NY.
Kathryn A PetersonUniversity of Utah Health, Salt Lake City, Utah.
Diane WhalleyRTI Health Solutions, Manchester, United Kingdom.
Shanshan QinRTI Health Solutions, Research Triangle Park, NC.
Sarette T TiltonSanofi Global, Bridgewater, NJ.
Siddhesh KamatRegeneron Pharmaceuticals, Inc, Sleepy Hollow, NY.
Xian SunRegeneron Pharmaceuticals, Inc, Sleepy Hollow, NY.
Evan S DellonUniversity of North Carolina School of Medicine, Chapel Hill, NC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of the esophagus leading to symptoms of esophageal dysfunction; dysphagia is the most common symptom experienced by adults and adolescents. Objective: We sought to perform a psychometric evaluation of the Dysphagia Symptom Questionnaire (DSQ), a patient-reported outcome measure for patients with EoE. Methods: Using baseline and week 24 data from the randomized, interventional, multinational phase 3 R668-EE-1774 trial (NCT03633617), the measurement properties of the DSQ-including reliability, construct and known-groups validity, responsiveness, and interpretation of change-were evaluated. Results: The analysis population comprised 239 patients with EoE (age [mean ± SD], 28.1 ± 13.14 years; 63.6% male; 90.4% White). Intraclass correlation coefficients of 0.92 and 0.97 exceeded the acceptable reliability threshold (≥0.70). Construct validity correlations with EoE symptom and impact measures were moderate at baseline (| Conclusions: This analysis confirmed that the DSQ has acceptable distributional properties, test-retest reliability, construct validity, and ability to detect change. Therefore, the DSQ is a valid and reliable measure to assess the patient-reported symptom of dysphagia among adult and adolescent patients with EoE in the context of a clinical trial setting.

Indexed as

dysphagiaEosinophilic esophagitispatient-reported outcomes measuresymptomsvalidation

Identifiers

PMID39228895
PMCPMC11369371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.